Clinical outcome of pretreated B-cell chronic lymphocytic
leukemia following alemtuzumab therapy: a retrospective study
on various cytogenetic risk categories.

J 2010

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.

FIEGL, M.; M. ERDEL; I. TINHOFER; Yvona BRYCHTOVÁ; Anna PANOVSKÁ et al.

Základní údaje

Originální název

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.

Autoři

Vydání

Annals of Oncology, 2010, 0923-7534

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 6.452

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051755

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1093/annonc/mdq236

UT WoS

000284636800016

Klíčová slova anglicky

alemtuzumab; chronic lymphocytic leukemia; cytogenetic abnormalities; FISH

Příznaky

Mezinárodní význam

Změněno: 12. 4. 2012 16:07, Mgr. Michal Petr

Anotace

V originále

Patients and methods: Data were collected from 105 consecutive, pretreated, cytogenetically defined patients who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) were assessed. Results: The hierarchic incidence of cytogenetic abnormalities was: 13q deletion (as sole abnormality), 18%; trisomy 12, 13%; 11q deletion, 19%; 17p deletion, 33%; and none of these, 16%. Overall response rate (ORR) was 43% in the total cohort and 49% in the subgroup of 17p-deleted patients (n = 35). From the start of alemtuzumab monotherapy, median PFS in the total cohort and in the subgroup of 17p-deleted patients was 7.0 and 7.1 months, respectively. Median OS in the total cohort and in 17p-deleted patients was 32.8 and 19.1 months, respectively. The poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n = 20) showed encouraging ORR, PFS, and OS (35%, 7.0 and 19.2 months, respectively). Conclusions: Alemtuzumab was effective in treating patients with CLL across the cytogenetic categories evaluated, but there were differences. In patients with CLL with 17p deletion quite favorable ORR, PFS, and OS were achieved.

Citovat

FIEGL, M.; M. ERDEL; I. TINHOFER; Yvona BRYCHTOVÁ; Anna PANOVSKÁ; Michael DOUBEK; K. EIGENBERGER; C. FONATSCH; G. HOPFINGER; H. MÜHLBERGER; A. ZABERNIGG; F. FALKNER; G. GASTL; Jiří MAYER a R. GREIL. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Annals of Oncology. 2010, roč. 21, č. 12, s. 2410-2419. ISSN 0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdq236.

@article{921538,
   author = {Fiegl, M. and Erdel, M. and Tinhofer, I. and Brychtová, Yvona and Panovská, Anna and Doubek, Michael and Eigenberger, K. and Fonatsch, C. and Hopfinger, G. and Mühlberger, H. and Zabernigg, A. and Falkner, F. and Gastl, G. and Mayer, Jiří and Greil, R.},
   article_number = {12},
   doi = {https://doi.org/10.1093/annonc/mdq236},
   keywords = {alemtuzumab; chronic lymphocytic leukemia; cytogenetic abnormalities; FISH},
   language = {eng},
   issn = {0923-7534},
   journal = {Annals of Oncology},
   title = {Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.},
   volume = {21},
   year = {2010}
}

TY  - JOUR
ID  - 921538
AU  - Fiegl, M. - Erdel, M. - Tinhofer, I. - Brychtová, Yvona - Panovská, Anna - Doubek, Michael - Eigenberger, K. - Fonatsch, C. - Hopfinger, G. - Mühlberger, H. - Zabernigg, A. - Falkner, F. - Gastl, G. - Mayer, Jiří - Greil, R.
PY  - 2010
TI  - Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
JF  - Annals of Oncology
VL  - 21
IS  - 12
SP  - 2410-2419
EP  - 2410-2419
SN  - 09237534
KW  - alemtuzumab
KW  - chronic lymphocytic leukemia
KW  - cytogenetic abnormalities
KW  - FISH
N2  - Patients and methods: Data were collected from 105 consecutive, pretreated, cytogenetically defined patients who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) were assessed. Results: The hierarchic incidence of cytogenetic abnormalities was: 13q deletion (as sole abnormality), 18%; trisomy 12, 13%; 11q deletion, 19%; 17p deletion, 33%; and none of these, 16%. Overall response rate (ORR) was 43% in the total cohort and 49% in the subgroup of 17p-deleted patients (n = 35). From the start of alemtuzumab monotherapy, median PFS in the total cohort and in the subgroup of 17p-deleted patients was 7.0 and 7.1 months, respectively. Median OS in the total cohort and in 17p-deleted patients was 32.8 and 19.1 months, respectively. The poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n = 20) showed encouraging ORR, PFS, and OS (35%, 7.0 and 19.2 months, respectively). Conclusions: Alemtuzumab was effective in treating patients with CLL across the cytogenetic categories evaluated, but there were differences. In patients with CLL with 17p deletion quite favorable ORR, PFS, and OS were achieved.
ER  -

FIEGL, M.; M. ERDEL; I. TINHOFER; Yvona BRYCHTOVÁ; Anna PANOVSKÁ; Michael DOUBEK; K. EIGENBERGER; C. FONATSCH; G. HOPFINGER; H. MÜHLBERGER; A. ZABERNIGG; F. FALKNER; G. GASTL; Jiří MAYER a R. GREIL. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. \textit{Annals of Oncology}. 2010, roč.~21, č.~12, s.~2410-2419. ISSN~0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdq236.

Přehled o publikaci